The hot category of initial public offerings in the biotechnology sector continues, as two started trading Friday — Seer (SEER) and Silverback Therapeutics (SBTX). Both the Silverback and Seer IPOs priced above their estimated range late Thursday.
X
The Seer IPO soared by triple digits. It raised $175 million by offering 9.2 million shares at $19, above the projected range of $16 to $18, providing it a fully diluted market value of $1.3 billion. As trading began, Seer stock quickly jumped 155%, near 47.60 on the stock market today.
The company is developing next-generation proteome analysis tests for biomedical research.
The lead underwriters of the Seer IPO, which will trade on the Nasdaq, are JPMorgan and Morgan Stanley.
Silverback jumped by double digits. it raised $242 million by offering 11.5 million shares at 21, above the range of 19 to 20. It originally planned to offer 10 million shares. The company has a fully diluted market value of $758 million. Sear stock jumped 33%, near 28.
Lead underwriters for the Silverback IPO, which will also trade on the Nasdaq, are Goldman Sachs, SVB Leerink and Stifel.
Silverback, Seer IPOs: Health Care Leads Charge
There have been 201 IPOs this year, up 32% from the same period last year, with about half coming from the health care sector, according to Renaissance Capital. Renaissance manages exchange traded funds focused on recent IPOs.
On Thursday, Kinnate Biopharma (KNTE) raised $240 million with an initial public offering that doubled in price on its first day of trading. Kinnate offered 12 million shares at 20, above the estimated range of 18 to 19. It originally planned to offer 10 million shares at 16 to 18.
The company focuses on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
Kinnate stock soared 95% Thursday, closing at 39.03. Kinnate was down 6.6%, near 38.23, during morning trading on the stock market today.
Recent IPOs are where you often find some of the market’s best stocks. Also, companies that bring new IPOs to market are typically in their early stages of growth, and it’s big earnings growth that generally fuels a stock’s price performance.
Please follow Brian Deagon on Twitter at @IBD_BDeagon for more on tech stocks, analysis and financial markets.
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD’s ETF Market Strategy
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Looking For Market Insights? Check Out Our IBD Live Daily Segment
